AI in Multiomics Market: Emerging Trends, Key Innovations, Growth Drivers & Market Opportunities
According to a new report published by Polaris Market Research, the global AI in Multiomics market was valued at USD 749.41 million in 2025 and is projected to reach USD 6,021.56 million by 2034, expanding at a CAGR of 26.05% during the forecast period.
Market Overview:
The market has witnessed strong momentum in recent years, propelled by the rising integration of artificial intelligence with genomics, transcriptomics, proteomics, metabolomics, and epigenomics data streams. Growing demand for AI-powered bioinformatics platforms capable of multi-omics data integration is enabling researchers to move from fragmented, single-layer analysis toward a unified view of disease biology. Increasing investment in precision medicine, expanding pharmaceutical R&D pipelines, and continuous advances in genomic AI interpretation are further accelerating adoption across research and clinical settings. Market participants are prioritizing cloud bioinformatics capabilities, spatial multiomics innovation, and strategic partnerships to strengthen their market share, and demand is expected to remain resilient through the forecast period as healthcare systems shift toward biomarker-driven, personalized care.
Key Market Insights:
The market was valued at USD 749.41 million in 2025, with the software segment leading at a 48.36% share on the back of growing AI-powered bioinformatics and multi-omics data integration platforms.
North America led the market in 2025 with approximately 39.68% of global revenue, while Asia Pacific is on track to post the fastest regional growth through 2034.
Genomics remained the dominant omics type in 2025 at a 31.72% share, even as spatial multiomics and precision & personalized medicine emerge as the fastest-growing categories, at CAGRs of 27.47% and 31.86% respectively.
Competitive activity is intensifying: 10x Genomics acquired Proteintech Genomics in June 2026 to expand its proteomics and single-cell research capabilities, while QIAGEN N.V. and NVIDIA Corporation partnered in May 2026 on graph-based AI for drug discovery.
Market Dynamics:
Driver: Rising adoption of precision medicine is increasing demand for AI-assisted biomarker identification and genomic AI interpretation across research and healthcare organizations.
Driver: Expanding use of AI-based drug discovery is helping pharmaceutical and biotechnology companies accelerate target identification and reduce development costs.
Restraint: Integrating heterogeneous omics data types while maintaining data quality, interoperability, and regulatory compliance remains a persistent challenge.
Restraint: A shortage of trained bioinformatics and computational biology professionals is limiting the pace of platform deployment across some organizations.
Opportunity: Expanding applications in regenerative medicine, stem cell research, and organoid commercialization are opening new avenues for AI-powered multiomics platforms.
Opportunity: Growing adoption of cloud bioinformatics is lowering infrastructure costs and enabling scalable multiomics data analysis in emerging markets across Asia Pacific and Latin America.
Competitive Landscape:
The market is moderately fragmented, with competition spanning biotechnology companies, sequencing technology providers, AI software developers, cloud platform providers, and bioinformatics firms. Companies compete on AI capabilities, multiomic data platform performance, data integration, scalability, and precision medicine applications. Key market players are emphasizing partnerships, mergers and acquisitions, new product launches, and continued investment in AI-based analytics to gain a competitive edge, while also expanding capabilities in proteomics integration, spatial multiomics, and foundation models in biology to strengthen biomarker discovery and genomic AI interpretation.
𝐌𝐚𝐣𝐨𝐫 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬:
Agilent Technologies
Bayer Crop Science
Bio Rad Laboratories, Inc.
BGI Group
Bruker Corporation
Charles River Laboratories
Corteva Agriscience
Danaher Corporation (Beckman Coulter)
DNAnexus, Inc.
F. Hoffmann La Roche Ltd.
Fabric Genomics, Inc.
Illumina, Inc.
Inari Agriculture
Microsoft Corporation
NVIDIA Corporation
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:
Recent Developments:
July 2026: Tempus AI, Inc. announced the nationwide launch of its OneOme pharmacogenomics test, supporting DNA-based drug selection and personalized therapies.
June 2026: 10x Genomics acquired Proteintech Genomics to extend its proteomics capabilities and strengthen its position in multiomics and single-cell research.
May 2026: QIAGEN N.V. partnered with NVIDIA Corporation to combine NVIDIA's BioNeMo platform with QIAGEN Digital Insights' biomedical knowledge base for graph-based AI drug discovery.
Market Segmentation:
By Component Outlook (Revenue, USD Million, 2021–2034)
Software
Hardware
Services
By Omics Type Outlook (Revenue, USD Million, 2021–2034)
Genomics
Transcriptomics
Proteomics
Metabolomics
Epigenomics
Spatial Multiomics
By Deployment Outlook (Revenue, USD Million, 2021–2034)
Cloud
On-Premises
Hybrid
By Application Outlook (Revenue, USD Million, 2021–2034)
Drug Discovery & Development
Precision & Personalized Medicine
Biomarker Discovery
Clinical Diagnostics
Agricultural Research
Others
By End User Outlook (Revenue, USD Million, 2021–2034)
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Healthcare Providers
Contract Research Organizations (CROs)
Others
Regional Insights:
North America: Held the largest share in 2025 at approximately 39.68% of global revenue, supported by strong biotechnology research activity, pharmaceutical investment, advanced sequencing infrastructure, and rapid AI adoption.
Asia Pacific: Expected to register the fastest growth during the forecast period, driven by rising biotechnology investment and AI adoption across China, Japan, India, South Korea, and Australia.
Europe: Maintained a substantial share in 2025, supported by increasing application of AI in life sciences and healthcare-innovation-focused regulation such as the EU AI Act and the EU4Health Programme.
Latin America & Middle East and Africa: Emerging growth regions, led by Brazil, Mexico, Saudi Arabia, the UAE, and South Africa as governments expand genomics research and precision medicine initiatives.
Future Outlook:
The future of the AI in Multiomics Market is expected to remain strong as artificial intelligence increasingly transforms genomic, proteomic, metabolomic, and transcriptomic data analysis. Growing adoption of precision medicine and personalized healthcare will create new opportunities for AI-powered multiomics platforms. Advances in machine learning and deep learning are likely to improve disease prediction, biomarker discovery, and therapeutic development. Increasing integration of multiomics with clinical and real-world datasets may further enhance research outcomes. Pharmaceutical and biotechnology companies are expected to expand investments in AI-driven drug discovery and target identification. Overall, technological advancements and expanding applications across healthcare and life sciences are likely to support sustained market growth.
Comments